Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Jul;34(4):263-71.

3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder

Affiliations

3-Nitrotyrosine and glutathione antioxidant system in patients in the early and late stages of bipolar disorder

Ana Cristina Andreazza et al. J Psychiatry Neurosci. 2009 Jul.

Abstract

Background: There has been an increasing interest in the role of oxidative stress in the pathophysiology of bipolar disorder. To explore this further, we evaluated the activity of glutathione peroxidase (GPx), glutathione reductase (GR) and glutathione S-transferase (GST), as well as 3-nitrotyrosine levels and carbonyl content in patients in the early (within 3 years of illness onset) and late (a minimum of 10 years of illness) stages of bipolar disorder.

Methods: We matched 30 patients in the early stage and 30 patients in the late stage of bipolar disorder, diagnosed according to DSM-IV criteria, with 60 healthy controls (30 matched for each group of patients). We measured symptomatic status using the Hamilton Rating Scale for Depression and the Young Mania Rating Scale.

Results: We found a significant increase in 3-nitrotyrosine levels among patients in the early (p < 0.010) and late (p < 0.010) stages of bipolar disorder. The activity of GR and GST was increased only among patients in the late stage of illness. Glutathione peroxidase activity and carbonyl content did not differ among the groups.

Limitations: Limitations of our study include its cross-sectional design, which did not allow us to examine direct causative mechanisms or the effects of progression of illness, and the potential environmental bias introduced by comparing patient groups recruited from different regions of the world.

Conclusion: Our data indicate a possible tyrosine nitration-induced damage in patients with bipolar disorder that is present from the early stage of illness. Our data also indicate that patients in the late stage of illness demonstrate enhanced activity of GR and GST, which could suggest the involvement of a compensatory system in bipolar disorder.

PubMed Disclaimer

Figures

Fig. 1
Fig. 1
(A) Glutathione peroxidase, (B) glutathione reductase and (C) glutathione S-transferase activity in serum samples from patients in the early (0–3 years of illness) and late (10–20 years of illness) stages of bipolar disorder. Results are expressed as means and standard deviations. *We compared groups using 1-way analysis of variance, followed by post-hoc analysis using the Tukey test (p < 0.001).
Fig. 2
Fig. 2
Levels of (A) protein oxidation (carbonyl levels) and (B) tyrosine nitration–induced damage (3-nitrotyrosine) in serum samples from patients in the early (0–3 years of illness) and late (10–20 years of illness) stages of bipolar disorder. Results are expressed as means and standard deviations. *We compared groups using 1-way analysis of variance, followed by post-hoc analysis using the Tukey test (p < 0.001).
Fig. 3
Fig. 3
Correlation between glutathione reductase (GR) or glutathione S-transferase (GST) levels with duration of illness in all patients with bipolar disorder (n = 60). The duration of illness positively correlates with GR levels (R2 = 0.242) and GST (R2 = 0.111).

References

    1. Belmaker RH. Medical progress: bipolar disorder. N Engl J Med. 2004;351:476–86. - PubMed
    1. Sajatovic M. Bipolar disorder: disease burden. Am J Manag Care. 2005;11(Suppl):S80–4. - PubMed
    1. Kupfer DJ. The increasing medical burden in bipolar disorder. JAMA. 2005;293:2528–30. - PubMed
    1. Merikangas KR, Akiskal HS, Angst J, et al. Lifetime and 12-month prevalence of bipolar spectrum disorder in the National Comorbidity Survey replication. Arch Gen Psychiatry. 2007;64:543–52. - PMC - PubMed
    1. McIntyre RS, Konarski JZ, Soczynska JK, et al. Medical comorbidity in bipolar disorder: implications for functional outcomes and health service utilization. Psychiatr Serv. 2006;57:1140–4. - PubMed